MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (1648)	1/12/2006 9:26:15 AM
From: sammaster	of 1826

aloxi sales to outpatient oncology offices and hospital based "outpatient" chemo center sales would not decline as they receive higher reibursement for aloxi over generic zofran... according to their presentations this seems to be their main market right now so these sales are "protected" from generic zofran.. i do agree that on the inpatient side that hospitals will switch wholeheartedly to cheaper generic zofran.. it seems like oral aloxi tabs when they get approval will have pressure of cheaper outpatient scripts of zofran.. however if aloxi truly does control nausea better and longer and truly reduces post op nausea recovery or inpatient chemo recovery and thus reduce length of stay in hospital then aloxi would be preffered over generic zofran... it would take a lot of doses of cost savings from generic zofran to make up for the cost of 1 patient staying in the hospital 1 more day because of nausea/vomitting...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next